BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 8, 2010
View Archived Issues
Dengue virus therapy AVI-6006 shows promise in animal models
Read More
Intranasal GI.1 norovirus virus-like particle vaccine is safe and efficacious in healthy volunteers
Read More
Quadrivalent Fluzone QIV is as safe and immunogenic as trivalent flu vaccines
Read More
AN-3661 is efficacious against Plasmodium infections in mice
Read More
Marina Biotech receives approval for CEQ-508 trial in familial adenomatous polyposis
Read More
Advanced Life Sciences enters into CRADA to advance Restanza for malaria
Read More
Bayer Schering Pharma claims new neutrophil elastase inhibitors
Read More
Bristol-Myers Squibb and Simcere to jointly develop BMS-817378
Read More
FDA approves Cymbalta for management of chronic musculoskeletal pain
Read More
New cytotoxic agents described for colon cancer therapy
Read More
Provectus plans course of action for approval of PV-10 in Australia
Read More
Advaxis and NCI enter into CRADA to develop Listeria vaccines
Read More
Shire provides update on progress of third quarter 2010
Read More
Italian scientists present new inhibitors of HCV NS5B
Read More
Phase III data reported on crofelemer for diarrhea in HIV-infected persons on antiretroviral therapy
Read More
Sanofi-aventis presents new inhibitors of PDE7 and/or PDE8
Read More
Boehringer Ingelheim identifies new reverse transcriptase inhibitors
Read More
Alnylam grants property license to Tekmira for TKM-Ebola
Read More
Nicotine vaccine NIC-002 enters phase II study
Read More
FDA approves once-daily Kombiglyze XR tablets for type 2 diabetes
Read More
FDA clears Vitros intact parathyroid hormone assay
Read More
Primary endpoint met in phase IIa vidofludimus trial in inflammatory bowel disease
Read More
Kuros regains rights to KUR-112, KUR-212 and KUR-213
Read More
Phase IIb data reported on LIPO-102 for selective nonablative fat reduction
Read More
BMK.1 inhibitor XMD-8-92 inhibits tumor growth in vivo
Read More